Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Abstract

In treatment-naïve HCV genotype 1 patients, SVR was 95% in those treated for either 8 weeks or 12 weeks with ledipasvir and sofosbuvir. 8 week ledipasvir and sofosbuvir can reduce costs without compromising outcomes for those patients who qualify for such regimen.

Real‐world outcomes of unrestricted direct‐acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience

“…Current Australian guidelines are similar to internationally accepted indications for an 8‐week course of sofosbuvir/ledipasvir for genotype 1 subjects with a viral load <6 million IU/ml, at clinician discretion. Our finding of 98.3% SVR12 in this group exceeds published Phase IIb and real‐world studies of 88‐94% . The more frequent use of fibroelastography in detecting advanced fibrosis in our cohort rather than FIB‐4 definitions of cirrhosis may be one potential reason for this .…”

Treatment of hepatitis C: Results in real life

“…SVR12 rates were nearly identical (93.6% and 93.5%, respectively), suggesting that 8‐ and 12‐week courses of sofosbuvir/ledipasvir were equally effective, in line with EASL recommendations . Similarly, a real‐world cohort study of ledipasvir plus sofosbuvir in 826 genotype 1‐infected, treatment‐naïve patients showed no difference in SVR rates between the 2 durations (both 95%) . High SVR12 rates were also reported in the HCV‐TARGET population, supporting the 8‐week treatment regimen for eligible patients .…”

“…Current EASL guidelines recommend an 8‐12 week sofosbuvir/ledipasvir regimen in treatment‐naïve patients with genotype 1 . This regimen has been evaluated in several large‐scale real‐world studies with different durations, which also demonstrate high SVR rates and show that some subgroups may achieve an SVR with an 8‐week regimen …”

Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017

“…Recent real-world studies on treatment of HCV genotype 1 (HCV-1) infection demonstrated that 12 weeks of SOF/LDV, SOF + DCV or SOF/VEL is efficient for treatment of the HCV-1 infection in non-cirrhotic patients without previous history of HCV antiviral therapy (2,5,(10)(11)(12). Treatment with suboptimal regimen of SOF + Pegylated Interferon (PegIFN) + RBV with around 90% efficacy in HCV-1 is not recommended anymore (3).…”